Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

Investment Income

Investment income was $1.0 million for the third quarter 2009 compared to $2.8 million in the same period in 2008. The decrease was primarily due to lower effective interest rates as a result of market conditions as well as a change in the asset allocation of Onyx's investment portfolio.

Interest Expense

Interest expense of $2.3 million for the third quarter 2009 relates to the 4.0% convertible senior notes due 2016 issued in August 2009, and includes non-cash imputed interest expense of $1.0 million as a result of the application of ASC Subtopic 470-20 (formerly known as FSP APB 14-1).

Cash, Cash Equivalents and Marketable Securities

At September 30, 2009, cash, cash equivalents, and current and noncurrent marketable securities were $843.1 million, compared to $458.0 million at December 31, 2008. This increase was primarily due to net proceeds of debt and equity financings in August 2009 and cash generated from operations.

Nine-Month Results

Nexavar net sales, as recorded by Bayer, were $608.3 million and $501.3 million for the nine months ended September 30, 2009 and 2008, respectively. Non-GAAP net income for the nine months ended September 30, 2009 was $45.6 million, or $0.73 per diluted share, compared to non-GAAP net income of $45.9 million, or $0.81 per diluted share for the same period in 2008, excluding employee stock-based compensation expense, non-cash imputed interest expense related to the application of ASC Subtopic 470-20 (formerly known as FSP APB 14-1), acquisition related transaction costs and a payment to BTG International Limited in connection with the achievement of a development milestone in the ONX 0801 program. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income." For the nine months ended September 30, 2009, on a GAA
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... As reported by the Frederick News Post in the ... (8/17), a graduate of the Frederick County Drug Treatment Court has ... with the program. The graduate, Korey Shorb, put together a race ... walk. He plans to donate the proceeds of the event to ... helped him. Shorb, who graduated in 2008, admitted that he would ...
(Date:8/29/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Glass microfiber ... report then explores global and China’s top manufacturers ... Production value, and market share etc. , The ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... 2014 Dr. Parsa Mohebi M.D. has developed ... loss achieve great results in hair transplantation. One of ... , an FUE method that harvests facial hair for transplanting ... lets patients whose hair loss classification is 5 and above ... a great alternative for those advanced hair loss patients who ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
Breaking Medicine News(10 mins):Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... A large, national multi-center study of thousands of children ... has found that most of those with normal computed ... observation. Of the more than 13,500 children included ... abnormal CT scans or MRIs and none required neurosurgical ...
... than white Americans, even when they have some ... is so, researchers at Columbia University,s Mailman School ... Medicine, surveyed African American adults with recent oral ... findings provide insights into why disparities persist even ...
... DALLAS June 16, 2011 UT Southwestern Medical ... anesthetic drug ketamine produces a fast-acting antidepressant response in ... robust effect at low doses as a fast-acting antidepressant ... "Ketamine produces a very sharp increase that ...
... esophagus may have a lower risk of esophageal cancer ... published online June 16 in the Journal of ... a premalignant condition, and patients who have it are ... signs of esophageal adenocarcinoma, the most common kind of ...
... -- The risk of cancer associated with the condition ... thought, according to a new long-term study. ... undergo routine endoscopies to screen for esophageal adenocarcinoma, a ... a long, thin tube with a camera at the ...
... Louis Children,s Hospital in the summer of 2010 near death ... lungs. Washington University physicians and surgeons at St. Louis ... his life. They collaborated to make several strategic and innovative ... artificial lung in a toddler. Their efforts are reported ...
Cached Medicine News:Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 2Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 3Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 2Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 3Health News:Barrett's esophagus carries lower risk of malignancy than previously reported 2Health News:Cancer Risk With Barrett's Esophagus May Be Lower Than Thought 2Health News:Washington University surgeons successfully use artificial lung in toddler 2Health News:Washington University surgeons successfully use artificial lung in toddler 3Health News:Washington University surgeons successfully use artificial lung in toddler 4
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct ... and other chronic wounds by the Saudi Food and Drug ... a living cell based product used by physicians to heal ... world. "With diabetes being a widespread and growing ...
... 28 Boston Scientific Corporation (NYSE: BSX ... long-term data from the MADIT II clinical trial in ... demonstrates that the life-saving benefits of implantable cardioverter defibrillator ... the first time that long-term data regarding the benefits ...
Cached Medicine Technology:Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 3
... important part of managing the disease state ... mean delivering the aerosolized medication to the ... medication waste. Aerosol delivery with the Salter ... including the new NebuTech® HDN®, helps to ...
Wire-wave tongs...
Tongs...
... vitro Nucleic Acid Hybridization Assay ... Chemiluminescence for the Qualitative Detection ... 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 and Analysis ... Groups in Cervical Specimens: HPV ...
Medicine Products: